Driving Clinical Development for accessible care

The need for breakthrough therapies in the world is unbroken with thousands of diseases still waiting for a cure or effective therapy and millions of patients not having access to therapies. At the same time, demand towards innovative pharma companies to meet this demand keep increasing through more complex therapeutic platforms, tighter access restrictions and smaller patient target populations. To address this, Pharma companies need to find ways to drive more innovation with the same or fewer resources. One key lever in this is maximizing value from investment into data through innovative secondary uses both of clinical patient data as well as operational data and implementing those efficiently at scale. In this session we will explore successful examples of those secondary data use solutions to optimize clinical development end-to-end for increased therapeutic benefit and feasibility as well as operational efficiency. This includes the benefits observed but also key learnings to overcome common challenges around creating sufficient adoption momentum, cost-effective scaling and management of interdependencies with broader capability builds in data and analytics as well as future expectations.